Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-4280A in selected solid tumors
NL-OMON59736Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of favezelimab, pembrolizumab and lenvatinib in cutaneous squamous cell carcinoma (cSCC) and endometrial cancer (EC) (4 cohorts), sponsored by Merck & Co. Primary endpoints: Clinical benefit and Objective response rate. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON59736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59736.